World Health Organization Group 5 Drugs for the Treatment of Drug-Resistant Tuberculosis: Unclear Efficacy or Untapped Potential?
Open Access
- 17 July 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 207 (9), 1352-1358
- https://doi.org/10.1093/infdis/jis460
Abstract
Background. Treatment of multidrug-resistant or extensively drug-resistant tuberculosis (DR-tuberculosis) is challenging because commonly used second-line drugs are poorly efficacious and highly toxic. Although World Health Organization group 5 drugs are not recommended for routine use because of unclear activity, some may have untapped potential as more efficacious or better tolerated alternatives. Methods. We conducted an exhaustive review of in vitro, animal, and clinical studies of group 5 drugs to identify critical research questions that may inform their use in current treatment of DR-tuberculosis and clinical trials of new DR-tuberculosis regimens. Results. Clofazimine may contribute to new short-course DR-tuberculosis regimens. Beta-lactams merit further evaluation—specifically optimization of dose and schedule. Linezolid appears to be effective but is frequently discontinued due to toxicity. Thiacetazone is too toxic to warrant further evaluation. Mycobacterium tuberculosis has intrinsic inducible resistance to clarithromycin. Conclusions. Clofazimine and beta-lactams may have unrealized potential in the treatment of DR-tuberculosis and warrant further study. Serious toxicities or intrinsic resistance limit the utility of other group 5 drugs. For several group 5 compounds, better understanding of structure-toxicity relationships may lead to better-tolerated analogs.Keywords
This publication has 47 references indexed in Scilit:
- Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone OxidoreductaseJournal of Biological Chemistry, 2011
- Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillinNature Medicine, 2010
- Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosisScience, 2009
- Comprehensive Treatment of Extensively Drug-Resistant TuberculosisNew England Journal of Medicine, 2008
- Irreversible Inhibition of the Mycobacterium tuberculosis β-Lactamase by ClavulanateBiochemistry, 2007
- Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2007
- Crystal Structure and Activity Studies of the Mycobacterium tuberculosis β-Lactamase Reveal Its Critical Role in Resistance to β-Lactam AntibioticsAntimicrobial Agents and Chemotherapy, 2006
- Intrinsic Macrolide Resistance of the Mycobacterium tuberculosis Complex Is InducibleAntimicrobial Agents and Chemotherapy, 2006